NCT02128243 - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer | Biotech Hunter

Enrollment

242

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 8, 2020

Study Completion Date

October 8, 2020

Conditions

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal JunctionGastric NeoplasmGastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaGastric AdenocarcinomaEsophageal Neoplasms

Interventions

DRUG

S-1 de-escalation

S-1 30 mg/m² bid d1-14 q21d

DRUG

Chemotherapy by Investigator's choice

"Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT"

Trial Locations (1)

69120

NCT-Med. Onkologie, Heidelberg